Harvard Apparatus Regenerative Technology (HRGN) is a clinical-stage biotechnology company focused on developing innovative solutions for organ regeneration using a patient's own stem cells. Their primary technology, known as Cellframe/Cellspan, involves a multistep process where mesenchymal stem cells are harvested from a simple adipose tissue biopsy, expanded, and then seeded onto a biocompatible scaffold that mimics the natural dimensions of the organ being targeted for regeneration. This scaffold is designed to interact with the stem cells in a way that signals the body’s regenerative processes, facilitating the restoration of damaged organ tissues. The company is currently conducting clinical trials, including a Phase 1 trial for severe esophageal disease, which highlights the potential of their technology to address critical medical needs.

HRGN's approach to organ regeneration emphasizes the use of the body's own biological resources in conjunction with specialized biomaterials. The Cellframe/Cellspan technology aims to provide the necessary cues to guide and modulate the regenerative process, making it a personalized solution for patients. This technology is particularly focused on replacing diseased sections of the esophagus, trachea, and bronchus, which are conditions that currently lack effective treatment options. By leveraging the body's inherent healing capabilities, HRGN is positioned to make significant advancements in regenerative medicine and improve outcomes for patients suffering from life-threatening conditions.

United States

HRGN is a clinical-stage biotechnology company that uses a patient’s own stem cells that are grown on a hollow tubular scaffold to regenerate organ tissue damaged from cancer, trauma, birth defects or other diseases.

Harvard Apparatus Regenerative Technology

Company Details